Visit to Fujifilm Biotechnologies Manufacturing Facility
2025/9/19
On Friday 19th September, Consul General Katsutoshi Takeda visited the Fujifilm Biotechnologies manufacturing (CDMO) facility located in Teesside, North East England.
The site itself currently employs approximately 1,200 people. Utilising an additional investment of £560 million, the UK’s largest facility for dedicated gene therapy drug processing development and active pharmaceutical ingredient manufacturing is being constructed on the site and is scheduled to be operational in 2026. Fujifilm Biotechnologies boasts high technical capabilities and productivity, having developed a continuous production system that integrates everything from cell culture to purification, making it a first in the CDMO industry.
To meet the growing demand for cutting-edge gene therapies and antibody drugs used for a wide range of diseases which are provided by the Fujifilm Biotechnologies, it is essential to not only expand the facilities but also to have highly specialised personnel. For this reason, the company has established a Centre of Excellence (CoE) with the University of Edinburgh, the University of York, and the University of Manchester. Through this, it is actively engaged in academic collaboration and human resource development, including support for 25 doctoral students.
The site itself currently employs approximately 1,200 people. Utilising an additional investment of £560 million, the UK’s largest facility for dedicated gene therapy drug processing development and active pharmaceutical ingredient manufacturing is being constructed on the site and is scheduled to be operational in 2026. Fujifilm Biotechnologies boasts high technical capabilities and productivity, having developed a continuous production system that integrates everything from cell culture to purification, making it a first in the CDMO industry.
To meet the growing demand for cutting-edge gene therapies and antibody drugs used for a wide range of diseases which are provided by the Fujifilm Biotechnologies, it is essential to not only expand the facilities but also to have highly specialised personnel. For this reason, the company has established a Centre of Excellence (CoE) with the University of Edinburgh, the University of York, and the University of Manchester. Through this, it is actively engaged in academic collaboration and human resource development, including support for 25 doctoral students.